Cadisegliatin

Cadisegliatin
Names
	IUPAC name [(2-{[Cyclohexyl(trans-4-propoxycyclohexyl)carbamoyl]amino}-1,3-thiazol-5-yl)sulfanyl]acetic acid
Identifiers
CAS Number	859525-02-3;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL5095262;
ChemSpider	123963152;
PubChem CID	54673176;
UNII	98S8SH8UNF;
	InChI InChI=1S/C21H33N3O4S2/c1-2-12-28-17-10-8-16(9-11-17)24(15-6-4-3-5-7-15)21(27)23-20-22-13-19(30-20)29-14-18(25)26/h13,15-17H,2-12,14H2,1H3,(H,25,26)(H,22,23,27)/t16-,17- Key: HPGJSAAUJGAMLV-QAQDUYKDSA-N;
	SMILES CCCO[C@H]1CC[C@H](N(C(NC2=NC=C(SCC(O)=O)S2)=O)C3CCCCC3)CC1;
Properties
Chemical formula	C21H33N3O4S2
Molar mass	455.63 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Cadisegliatin (TTP399) is a liver-selective glucokinase activator. It is being developed by VTV Therapeutics for treatment of type 2 diabetes or type 1 diabetes as an adjunct to insulin.^[1]^[2]^[3]^[4]^[5]

References

^ Klein, Klara R.; Freeman, Jennifer L.R.; Dunn, Imogene; Dvergsten, Chris; Kirkman, M. Sue; Buse, John B.; Valcarce, Carmen; Buse, John B.; Klein, Klara R.; Kirkman, M. Sue; Bergamo, Katherine A.; Harris, Elizabeth H.; Dostou, Jean M.; Young, Laura A.; Machineni, Sriram; Kass, Alex M.; Diner, Jamie C.; Dezube, Milana; Purrington, Virginia C.; Uehling, Julie M.; Fraser, Rachael M.; Schuch, Katherine R.; Rowell, Jennifer V.; Qamar, Ali; Lucas, K. Jean; Snedaker, Luke; Hoover, Stephanie; Smith, Justin; Becton, Paul; Hainsworth, Jeffrey; Bailey, Timothy S.; Garcia-Naranjo, Juan Pablo; Nguyen, Niki; Bode, Bruce W.; Boyd, Jennifer M.; Childs, Betsy; Mora, Pablo; Camacho, Allison; Vance, Carl D.; Lugo, Karen; Bhargava, Anuj; Stifel, Kirstie; Connery, Lisa B.; Khan, Birjis; Smith, Simone D.; Parker, John; Zweier, Kathryn; Kronenfeld, Emily; Savoca, Brittany; Shah, Viral N.; Joshee, Prakriti; Dixit, Shivani; Joseph, Hal; Akturk, Halis Kaan; Trikudanathan, Subbulaxami; Khakpour, Dori; Chang, Julia; Peters, Anne; Cohan, Pejman; Harmel, Mark; . Lane, Wendy S (1 April 2021). "The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes". Diabetes Care. 44 (4): 960–968. doi:10.2337/dc20-2684. PMC 7985421. PMID 33622669.
^ Klein, Klara; Boeder, Schafer C.; Freeman, Jennifer L.; Madduri, Supradeep; Giovannetti, Erin R.; Valcarce, Carmen; Buse, John B.; Pettus, Jeremy (1 June 2022). "835-P: The Hepatoselective Glucokinase Activator (GKA) TTP399 Does Not Increase Risk of Ketoacidosis in Type 1 Diabetes (T1D)". Diabetes. 71 (Supplement_1). doi:10.2337/db22-835-P. S2CID 249260398.
^ Klein, Klara R.; Boeder, Schafer C.; Freeman, Jennifer L. R.; Dunn, Imogene; Dvergsten, Chris; Madduri, Supradeep; Giovannetti, Erin R.; Valcarce, Carmen; Buse, John B.; Pettus, Jeremy H. (August 2022). "Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes". Diabetes, Obesity and Metabolism. 24 (8): 1439–1447. doi:10.1111/dom.14697. PMC 9262835. PMID 35661378.
^ Vella, Adrian; Freeman, Jennifer L. R.; Dunn, Imogene; Keller, Kit; Buse, John B.; Valcarce, Carmen (16 January 2019). "Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator". Science Translational Medicine. 11 (475). doi:10.1126/scitranslmed.aau3441. PMID 30651321. S2CID 58031603.
^ Egan, Aoife; Vella, Adrian (2 September 2019). "TTP399: an investigational liver-selective glucokinase (GK) activator as a potential treatment for type 2 diabetes". Expert Opinion on Investigational Drugs. 28 (9): 741–747. doi:10.1080/13543784.2019.1654993. PMID 31398075. S2CID 199519440.

[1] Klein, Klara R.; Freeman, Jennifer L.R.; Dunn, Imogene; Dvergsten, Chris; Kirkman, M. Sue; Buse, John B.; Valcarce, Carmen; Buse, John B.; Klein, Klara R.; Kirkman, M. Sue; Bergamo, Katherine A.; Harris, Elizabeth H.; Dostou, Jean M.; Young, Laura A.; Machineni, Sriram; Kass, Alex M.; Diner, Jamie C.; Dezube, Milana; Purrington, Virginia C.; Uehling, Julie M.; Fraser, Rachael M.; Schuch, Katherine R.; Rowell, Jennifer V.; Qamar, Ali; Lucas, K. Jean; Snedaker, Luke; Hoover, Stephanie; Smith, Justin; Becton, Paul; Hainsworth, Jeffrey; Bailey, Timothy S.; Garcia-Naranjo, Juan Pablo; Nguyen, Niki; Bode, Bruce W.; Boyd, Jennifer M.; Childs, Betsy; Mora, Pablo; Camacho, Allison; Vance, Carl D.; Lugo, Karen; Bhargava, Anuj; Stifel, Kirstie; Connery, Lisa B.; Khan, Birjis; Smith, Simone D.; Parker, John; Zweier, Kathryn; Kronenfeld, Emily; Savoca, Brittany; Shah, Viral N.; Joshee, Prakriti; Dixit, Shivani; Joseph, Hal; Akturk, Halis Kaan; Trikudanathan, Subbulaxami; Khakpour, Dori; Chang, Julia; Peters, Anne; Cohan, Pejman; Harmel, Mark; . Lane, Wendy S (1 April 2021). "The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes". Diabetes Care. 44 (4): 960–968. doi:10.2337/dc20-2684. PMC 7985421. PMID 33622669.

[2] Klein, Klara; Boeder, Schafer C.; Freeman, Jennifer L.; Madduri, Supradeep; Giovannetti, Erin R.; Valcarce, Carmen; Buse, John B.; Pettus, Jeremy (1 June 2022). "835-P: The Hepatoselective Glucokinase Activator (GKA) TTP399 Does Not Increase Risk of Ketoacidosis in Type 1 Diabetes (T1D)". Diabetes. 71 (Supplement_1). doi:10.2337/db22-835-P. S2CID 249260398.

[3] Klein, Klara R.; Boeder, Schafer C.; Freeman, Jennifer L. R.; Dunn, Imogene; Dvergsten, Chris; Madduri, Supradeep; Giovannetti, Erin R.; Valcarce, Carmen; Buse, John B.; Pettus, Jeremy H. (August 2022). "Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes". Diabetes, Obesity and Metabolism. 24 (8): 1439–1447. doi:10.1111/dom.14697. PMC 9262835. PMID 35661378.

[4] Vella, Adrian; Freeman, Jennifer L. R.; Dunn, Imogene; Keller, Kit; Buse, John B.; Valcarce, Carmen (16 January 2019). "Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator". Science Translational Medicine. 11 (475). doi:10.1126/scitranslmed.aau3441. PMID 30651321. S2CID 58031603.

[5] Egan, Aoife; Vella, Adrian (2 September 2019). "TTP399: an investigational liver-selective glucokinase (GK) activator as a potential treatment for type 2 diabetes". Expert Opinion on Investigational Drugs. 28 (9): 741–747. doi:10.1080/13543784.2019.1654993. PMID 31398075. S2CID 199519440.

[1]

[2]

[3]

[4]

[5]

Names

IUPAC name [(2-{[Cyclohexyl(trans-4-propoxycyclohexyl)carbamoyl]amino}-1,3-thiazol-5-yl)sulfanyl]acetic acid
Identifiers
CAS Number	859525-02-3
3D model (JSmol)	Interactive image
ChEMBL	ChEMBL5095262
ChemSpider	123963152
PubChem CID	54673176
UNII	98S8SH8UNF
InChI InChI=1S/C21H33N3O4S2/c1-2-12-28-17-10-8-16(9-11-17)24(15-6-4-3-5-7-15)21(27)23-20-22-13-19(30-20)29-14-18(25)26/h13,15-17H,2-12,14H2,1H3,(H,25,26)(H,22,23,27)/t16-,17- Key: HPGJSAAUJGAMLV-QAQDUYKDSA-N
SMILES CCCO[C@H]1CC[C@H](N(C(NC2=NC=C(SCC(O)=O)S2)=O)C3CCCCC3)CC1
Properties
Chemical formula	C₂₁H₃₃N₃O₄S₂
Molar mass	455.63 g·mol⁻¹
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references